Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program

Go back to Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program
(NASDAQ: PROG) Delayed: 2.50 -0.08 (3.1%)
Previous Close $2.58    52 Week High
Open $2.58    52 Week Low
Day High $2.64    P/E N/A 
Day Low $2.44    EPS
Volume 919,462